FDA Releases Guidance on Electronic Submissions
The draft guidance describes how content should be organized in electronic submissions for all submission types under section 745A(a) of the FD&C Act.
FDA released guidance on July 16, 2019 that describes how applicants should organize the content they submit to the agency electronically. The guidance applies to all submission types under section 745A(a) of the Food, Drug, and Cosmetic (FD&C) Act. The guidance also references technical specification documents and the Electronic Common Technical Document Conformance (eCTD) Guide. Specifically, the guidance implements the electronic submission of content submitted in new drug applications (NDAs), abbreviated new drug applications (ANDAs), certain biologics license applications (BLAs), and certain investigational new drug applications (INDs) to the Center for Drug Evaluation and Research (CDER) or the Center for Biologics Evaluation and Research (CBER).
A previous version of this guidance, published in May 2015, indicated that NDAs, BLAs, ANDAs, and master files were to be submitted electronically in eCTD format starting on May 5, 2017 (May 5, 2018, for commercial INDs). In response to industry concerns, however, FDA extended the implementation date for drug master files (DMFs) to May 5, 2020. This new revision modifies previous versions by including exemptions for Type III DMFs. The guidance has also been updated to include the criteria identifying those types of submissions that may qualify for a long-term or short-term waiver from the eCTD submission requirement and instructions on how to submit a waiver request.
Comments on the draft guidance will be accepted until Sept. 16, 2019.
Source: FDA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
